Ashland launches permexa sodium caprate for oral drug delivery
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate
August 24, 2026 7:00 AM EDTCommercialization follows strong interest from pharmaceutical developers worldwide
WILMINGTON, Del., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH), is announcing the launch of permexa sodium caprate, a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines.Â
The launch comes at a time of significant market momentum in oral peptide and biologics development. Pharmaceutical companies continue to invest heavily in oral alternatives to injectable therapies, driven by the potential to improve... More
